- Great News for SoFi Investors: This Mastercard Deal Could Be Bigger Than It Looks
- The US Dollar Index fell on the 17th.
- API Crude Unexpectedly Falls by 1.7 Million Barrels as Geopolitical Risks Rise, Suggesting a Tighter Market
- API Crude Unexpectedly Drops by 1.7 Million Barrels as Geopolitical Risks Rise, Suggesting a Tighter Market
- Oil Supply Disruption Resists Stabilization—Strait of Hormuz Shutdown Drives Stagflation Trade Scenario
- Proton VPN's Swiss Privacy Protection: Essential Security for Crypto Traders Facing Surveillance and Exchange Limitations
- Floor And Decor (FND): Should You Buy, Sell, or Hold After Q4 Results?
- 1 AI stock that may catch investors off guard in 2026
- Andersen: Fourth Quarter Earnings Overview
- 1 Outstanding Industrial Stock Plunged 58%—A Smart Long-Term Investment
- Cibus: Fourth Quarter Financial Overview
- Philip Morris (PM): Should You Buy, Sell, or Hold After Q4 Results?
- Star Equity Holdings: Fourth Quarter Earnings Overview
- Star Equity Holdings: Fourth Quarter Earnings Overview
- Top Equity Analyses for GE Aerospace, Shell, and McKesson
- DOE's Centralia Coal Mandate Under Legal Fire: A Precedent for Costly Grid Interventions?
- Oklo’s Regulatory Flywheel Validates Atomic Alchemy’s Path to Isotope Self-Sufficiency
- FERC's Prudence Enforcement Precedent Risks Rewriting Utility Valuation Logic
- SEC And CFTC Unveil Joint Crypto Guidelines Reshaping Regulatory Landscape
- Crypto Adoption vs Currency Devaluation: Is There a Correlation?
- AgentKit's $43M Flow compared to $3T Vision
- 3 Reasons to Steer Clear of OCUL and One Alternative Stock Worth Buying
- 3 Reasons to Steer Clear of LAUR and 1 Alternative Stock Worth Buying
- SEC’s Approach to Cryptocurrency Regulation: Insights from Flow Data
- Trading Day: Oil back above $100... and so?
- Mastercard’s Recent Statement about Ripple Stuns XRP Army
- Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
- ORIC Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
- Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- Bitcoin Dominance Play: Strategy Adds Another Billion To Its Stack
- 10SET (Tenset) 24h Amplitude Reaches 348.0%: Price Plummets After Extreme Volatility, Trading Volume Surges Without Clear News Catalyst
- Stardust Power Reports Preliminary 2025 Results and Highlights Development Progress at Muskogee Lithium Refinery
- ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
- Auburn National Bancorporation Authorizes Stock Repurchase Program
- Nuvation Bio Presents 50-Month DOR at AACR 2026: Does IBTROZI’s Long-Term Efficacy Signal a Valuation Upside or Potential Mispricing?
- Can Tokenized Deposits Seize $3.9 Trillion in Same-Day ACH Transactions?
- Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
- Western Responses and Market Movements: Financial Indicators from the Iran Crisis
- CEE FX Flows: Carry Trades and Liquidity in the Context of the Energy Shock
- Churchill Downs (CHDN): Should You Buy, Sell, or Hold After Q4 Results?
- Is Meta Platforms shares on track to hit $700 before the year ends? The numbers suggest it's within reach.
- 3 Reasons Why DCOM is a Risky Choice and One Alternative Stock Worth Buying
- After releasing its latest financial results and future outlook, Comscore (stock code: SCOR) surged 15.6% in after-hours trading, closing at $8.30.
- Rocket Lab USA, Inc. shares fell 4.33% in after-hours trading, closing at $75.19.
- Colgate recently submitted a filing to the U.S. Securities and Exchange Commission, announcing that its business operations in the Russia and Belarus markets will be adjusted to be reported under the Asia-Pacific operations department.
- Colgate recently announced that the realignment of its reportable operating segments has not had a material impact on its historical consolidated operating results and financial condition.
- On March 11, Telix Pharmaceuticals announced that the acquirer of its acute care and urology business has received a request for additional information and documentary materials from the U.S. Federal Trade Commission (FTC).
- According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), medical device company Teleflex has clarified the timeline for transactions related to its acute care and urology business.
- According to the latest documents disclosed by the U.S. Securities and Exchange Commission, the power business division of DTE Energy has signed a twenty-year long-term contract to operate renewable energy generation and storage facilities.
- Gold Holds Steady Above $5,000 as Safe Haven Appeal Grows
- Raymond James (RJF): Should You Buy, Sell, or Hold After Q4 Results?
- 3 Reasons Why Armstrong World (AWI) Wins Our Hearts
- Curtiss-Wright Encounters Disparity in Expectations as Forecasts Ease Following 31% Surge
- Copper’s Paradox: Real-World Supply Tightness Meets Paper Market Excess Amid Tariff-Driven Inventory Hoarding in Warehouses
- Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
- Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the AACR Annual Meeting 2026
- How major US stock indexes fared Tuesday 3/17/2026
- FLD Surges 6.25% After Hours — With No Clear Catalyst
- CFTC Chairman says DeFi and prediction markets can restore trust
- Harte-Hanks: Fourth Quarter Earnings Overview
- Titan America: Fourth Quarter Earnings Overview
- MICRON hit top of 17-year Channel. -50% crash possible.
- $DUOL bags could have been avoided if you had heard the thesis!
- AAPL GEX - Testing HVL in a Volatile Regime
- $IONQ: Sovereign Capital Meets a Technical Bottom
- Fold Misses Q4 Revenue, Bitcoin Treasury Remains an Overlooked Upside Catalyst
- Moody’s brings credit ratings onchain with Canton Network integration
- Is Ripple Building a SWIFT Bank Oracle To Rival Chainlink?
- DocuSign's Strong Competitive Edge and Expanding IAM Strategy Present a Value Opportunity at Yearly Low Prices
- Kestra's Earnings Beat Masks Institutional Divide as FMR Buys, Citadel Sells
- Lululemon’s Guidance Raise Fails to Address Core U.S. Sales Slump—2026 Outlook Now the Real Make-or-Break Catalyst
- Where Could First Majestic Silver Stock Be Three Years From Now?
- SmartFinancial (SMBK) Fourth Quarter 2025 Earnings Call Transcript
- 3 Factors That Make BYD a Risky Choice and One Alternative Stock Worth Considering
- Wendy's (WEN): Should You Buy, Sell, or Hold After Q4 Results?
- USD/THB: Overbought but still upside risks – OCBC
- HIT Surges 27.7% Post-Market — But Volume Raises Red Flags
- Crypto Market Structure Bill: TD Cowen's Projected 2027 Postponement Compared to Present Market Dynamics
- Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial
- Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA
- Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
- Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
- Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
- COLLECT (COLLECT) 24-hour Volatility at 42.8%: Trading Volume Surges Driven by Leverage Trading Signals
- Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
- Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
- Parsons Announces New Chief Human Resources Officer
- SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference
- ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
- Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
- TransAlta Corporation Announces Conversion Results for Series A and B Preferred Shares
- Dogecoin Price Surges as Memecoins Jump 10%— Is This Rally Sustainable?
- Akari Therapeutics Announces ADS Ratio Change
- Every $1 Million Into XRP Is Moving the Market Cap by $490 Million: Here Is Why That Changes Everything
- Howmet's Position in Defense Aerospace Appears Solid: Is There More Room for Growth?
- MGRX Surges 14.3% in Post-Market Void
- XLE Encounters Supply Shock Alpha with Brent Surpassing $103 Due to Strait of Hormuz Shutdown and Limited Inventories
- HITI Breaks 20-Day High on Thin Volume as TPS Appeal Looms
- Spandex manufacturer pushed beyond limits as Lycra files for bankruptcy
